HBPCF (Helix BioPharma) Accumulated Depreciation: $-0.90 Mil (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HBPCF Helix BioPharma Corp HBPCF
32 GF Score
Price $1.71
View Full Analysis

What is Helix BioPharma Accumulated Depreciation?

Helix BioPharma HBPCF 32 Accumulated Depreciation is $-0.90 Mil as of Apr. 2026. GuruFocus rates HBPCF with a GF Score™ of 32/100.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Helix BioPharma's quarterly accumulated depreciation increased from Oct. 2025 ($-0.89 Mil) to Jan. 2026 ($-0.90 Mil) and increased from Jan. 2026 ($-0.90 Mil) to Apr. 2026 ($-0.90 Mil).

Helix BioPharma's annual accumulated depreciation declined from Jul. 2023 ($-1.36 Mil) to Jul. 2024 ($-1.32 Mil) but then stayed the same from Jul. 2024 ($-1.32 Mil) to Jul. 2025 ($-0.90 Mil).

Helix BioPharma Accumulated Depreciation Related Terms

Helix BioPharma Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Helix BioPharma's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helix BioPharma Accumulated Depreciation Chart

Helix BioPharma Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.41 -1.38 -1.36 -1.32 -0.90

Helix BioPharma Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.88 -0.90 -0.89 -0.90 -0.90
HBPCF
32GF Score
Helix BioPharma Corp HBPCF
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Helix BioPharma Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of $-0.90 Mil mean?
Helix BioPharma (HBPCF) has a Accumulated Depreciation of $-0.90 Mil as of Apr. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Helix BioPharma and its competitors.
Is Helix BioPharma's Accumulated Depreciation too high?
Helix BioPharma's current Accumulated Depreciation is $-0.90 Mil. Overall, Helix BioPharma has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's Accumulated Depreciation compare to VRTX and REGN?
Helix BioPharma's Accumulated Depreciation of $-0.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Helix BioPharma and its competitors. Helix BioPharma's current Accumulated Depreciation is $-0.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current Accumulated Depreciation of $-0.90 Mil. The current Accumulated Depreciation is $-0.90 Mil. Helix BioPharma's overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current Accumulated Depreciation is $-0.90 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helix BioPharma Business Description

Other Exchanges HBP0:GermanyHBP:Canada
Address 40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
32GF Score

Get the complete analysis for HBPCF

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.71
Price